Literature DB >> 3163337

New method for the determination of doxorubicin, 4'-epidoxorubicin and all known metabolites in cardiac tissue.

P A Maessen1, H M Pinedo, K B Mross, W J van der Vijgh.   

Abstract

4'-Epidoxorubicin, doxorubicin (internal standard) and eight metabolites were extracted from heart tissue homogenate by a mixture of tetrahydrofuran-water (1:2, v/v) and purified by C18 Sep-Pak cartridges. The buffer used to prepare the homogenate contained glucaric acid-1,4-lactone and glucose, to prevent decomposition of the 4'-epidoxorubicin glucuronides. Anthracyclines were separated by high-performance liquid chromatography within 14 min and detected by fluorescence. Recoveries ranged from 49 to 75%. The detection limits of the individual anthracyclines ranged from 0.5.10(-11) to 2.5.10(-11) mol/g wet weight. The peak-height ratios of the fluorescence intensities of the anthracyclines versus doxorubicin were linear from 2.5.10(-11) to 250.10(-11) mol/g wet weight. Within- and between-day precisions of the assay varied between the anthracyclines and were in the ranges 3-12% (n = 6) and 2-11% (n = 6), respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3163337     DOI: 10.1016/s0378-4347(00)81080-4

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

2.  Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors.

Authors:  K Mross; K Hamm; W Schultze-Seemann; K Burk; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Intravesical idarubicin--a phase-I study.

Authors:  W Schultze-Seemann; K Mross; K Burk; H Sommerkamp
Journal:  Urol Res       Date:  1994

4.  Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.

Authors:  J de Jong; I Klein; A Bast; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.

Authors:  W J van der Vijgh; P A Maessen; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.

Authors:  A López-Pousa; R Losa; J Martín; J Maurel; J Fra; M Sierra; A Casado; J García Del Muro; A Poveda; C Balañá; J Martínez-Trufero; E Esteban; J M Buesa
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.